The association between zinc deficiency, and clinical outcomes of COVID-19

Wu, Jheng‐Yan; Hsu, Wan‐Hsuan; Tsai, Ya‐Wen; Liu, Ting-Hui; Huang, Po‐Yu; Chuang, Min‐Hsiang; Chin, S.; Lai, Chih‐Cheng; Liu, Meiyuan

doi:10.1016/j.jinf.2023.06.021

Cited by 4 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TriNetX platform offers extensive electronic health records (EHRs) encompassing the details (i.e., data regarding diagnoses, procedures, medications, laboratory data, and genomic information). Furthermore, the reliability of the data source is well‐recognized for its comprehensive data set of COVID‐19 patients and has been effectively used to study a multitude of globally pertinent medical subjects, including research related to COVID‐19 26–29 . The study was approved by the Institutional Review Board of the Chi Mei Medical Center (approval no.…”

Section: Methodsmentioning

confidence: 99%

“…Furthermore, the reliability of the data source is well-recognized for its comprehensive data set of COVID-19 patients and has been effectively used to study a multitude of globally pertinent medical subjects, including research related to COVID-19. [26][27][28][29] The study was approved by the Institutional Review Board of the Chi Mei Medical Center (approval no. 11302-E01).…”

Section: Data Sourcementioning

confidence: 99%

See 1 more Smart Citation

Clinical effectiveness of nirmatrelvir plus ritonavir on the short‐ and long‐term outcome in high‐risk children with COVID‐19

Wu,

Chen,

Liu

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

This study investigated the clinical effectiveness of nirmatrelvir plus ritonavir (NMV‐r) on short‐term outcome and the risk of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection (PASC) among pediatric patients with coronavirus disease 2019 (COVID‐19). This retrospective cohort study used the TriNetX research network to identify pediatric patients between 12 and 18 years with COVID‐19 between January 1, 2022 and August 31, 2023. The propensity score matching (PSM) method was used to match patients receiving NMV‐r (NMV‐r group) with those who did not receive NMV‐r (control group). Two cohorts comprising 633 patients each (NMV‐r and control groups), with balanced baseline characteristics, were identified using the PSM method. During the initial 30 days, the NMV‐r group showed a lower incidence of all‐cause hospitalization, mortality, or ED visits (hazard ratio [HR] = 0.546, 95% confidence interval [CI]: 0.372–0.799, p = 0.002). Additionally, the NMV‐r group had a significantly lower risk of all‐cause hospitalization compared with the control group (HR = 0.463, 95% CI: 0.269–0.798), with no deaths occurring in either group. In the 30–180‐day follow‐up period, the NMV‐r group exhibited a non‐significantly lower incidence of post‐acute sequelae of SARS‐CoV‐2 infection (PASC), encompassing symptoms such as fatigue, cardiopulmonary symptoms, pain, cognitive impairments, headache, dizziness, sleep disorders, anxiety, and depression, compared to the control group. This study underscores the potential effectiveness of NMV‐r in treating high‐risk pediatric patients with COVID‐19, demonstrating significant reductions in short‐term adverse outcomes such as emergency department visits, hospitalization, or mortality within the initial 30‐day period. Additionally, NMV‐r shows promise in potentially preventing the development of PASC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Data Sourcementioning

confidence: 99%

Clinical effectiveness of nirmatrelvir plus ritonavir on the short‐ and long‐term outcome in high‐risk children with COVID‐19

Wu,

Chen,

Liu

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Zinc deficiency increases susceptibility to COVID-19 and is associated with anosmia, cytokine storm, and lung damage. 155 Pyrithione a is a known ionophore with the ability to bind zinc ions and transport them through lipid cell membranes, increasing their intracellular concentration. In 2010, Velthuis et al discovered that the combination of Zn 2+ and pyrithione could inhibit SARS-CoV infection.…”

Section: S/d4 Dual Inhibitorsmentioning

confidence: 99%

“…Zn 2+ have been shown to play an important role in SARS-CoV-2 infection. Zinc deficiency increases susceptibility to COVID-19 and is associated with anosmia, cytokine storm, and lung damage . Pyrithione a is a known ionophore with the ability to bind zinc ions and transport them through lipid cell membranes, increasing their intracellular concentration.…”

Section: Dual-target Inhibitors Of Sars-cov-2mentioning

confidence: 99%

New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs

Zhang,

Xiao,

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

The 2019 coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in millions of deaths, posing a serious threat to public health and safety. Rapid mutations of SARS-CoV-2 and complex interactions among multiple targets during infection pose a risk of expiry for small molecule inhibitors. This suggests that the traditional concept of "one bug, one drug" could be ineffective in dealing with the coronavirus. The dual-target drug strategy is expected to be the key to ending coronavirus infections. However, the lack of design method and improper combination of dual-targets poses obstacle to the discovery of new dual-target drugs. In this Perspective, we summarized the profiles concerning drug design methods, structure−activity relationships, and pharmacological parameters of dual-target drugs for the treatment of COVID-19. Importantly, we underscored how target combination and rational drug design illuminate the development of dualtarget drugs for SARS-CoV-2. ■ SIGNIFICANCE• This is the first Perspective on dual-target drugs for treating coronavirus. • Dual-target drugs, acting on multiple pathways, offer enhanced efficacy and can delay resistance compared to single-target treatments. • Drug repurposing for dual-target design can significantly shorten the timeline for clinical trials, addressing urgent medication needs during the early COVID-19 outbreak. • The introduction of covalent warheads can compensate for active site similarity issues, aiding in the development of high-affinity dual-target inhibitors.

show abstract

“…In the Journal of Infection Wu et al's [1] published an article on the relationship between zinc deficiency and COVID-19 clinical outcomes with great interest. According to the scientific literature, there is evidence to suggest a link between zinc (Zn) deficiency and poorer clinical outcomes in SARS-CoV-2 infections, notably in terms of all-cause mortality [2][3][4][5].…”

mentioning

confidence: 99%